Research published in the journal Retina show that a little over half of the studies into new interventional clinical trials in AMD are made available through peer-reviewed publication. The surprisingly low rate of publication may arise for a range of reasons however, the authors of the Retina study suggest that significant benefits are lost when full study results are unavailable to the wider retina community.